A total of 15,000 doses of injectable Lenacapavir (LEN) for use as a pre-exposure prophylaxis (PrEP) against HIV are expected ...

The Department of Health (DOH) has secured a donation of 15,000 doses of the long-acting injectable pre-exposure prophylaxis ...

ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Shionogi as a shareholder, today announced the ...

ViiV Healthcare is teaming up with TV personality, HIV and LGBTQ advocate Michelle Visage to help broaden awareness about new ...

Young men who have sex with men (YMSM) said the treatment’s efficacy was the most important feature injectable HIV pre-exposure prophylaxis (PrEP), over side effects, cost, protection duration, and ...

Add Yahoo as a preferred source to see more of our stories on Google. In a large clinical trial assessing Apretude, ViiV Healthcare’s recently approved injectable drug, as a form of HIV prevention, ...

Share on Pinterest Research finds a new injectable form of PrEP is superior to daily oral tablets to prevent the contraction of HIV. Sara Jurado/Getty Images New research sheds light on the efficacy ...

One year ago, the United States approved a new injectable drug that prevents HIV. After successful clinical trials, long-acting cabotegravir was found to be almost 100 per cent effective at preventing ...

A nurse at Tudor Sub-County Hospital in Mombasa administers Lenacapavir injection during the rollout of the vaccine on March 13, 2026. [Robert Menza, Standard] Mombasa County has officially rolled out ...

The federal Food and Drug Administration has approved Apretude (extended-release cabotegravir), the first long-acting injectable option for HIV prevention. The shots, which are administered by a ...

According to ABC News' latest report, almost 38,000 Americans are diagnosed with HIV (human immunodeficiency virus) every year. There are already treatments to prevent HIV infection. In 2012, the Food ...